ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE) | WebDisclosure

Basculer en Français

10964	Companies
240036	Keywords
168778	Articles
129136	Press releases

Headlines Articles Press releases ORPHAN SYNERGY EUROPE-PHARMA

Home
Companies
ORPHAN SYNERGY EUROPE-PHARMA

PRESS RELEASE

published on 10/15/2025 at 19:00, 10 months 26 days ago

OSE Immunotherapeutics Reports First Half 2025 Financial Results
OSE Immunotherapeutics reports first half 2025 financial results with operating loss of 15.8 million euros and net loss of 15.1 million euros. Research and development expenses increased 6.7%

Financial Results Net Loss Operating Loss OSE Immunotherapeutics Research And Development Expenses
PRESS RELEASE

published on 10/15/2025 at 19:00, 10 months 26 days ago

OSE Immunotherapeutics publie ses résultats financiers du 1er semestre 2025
OSE Immunotherapeutics publie ses résultats financiers du 1er semestre 2025, montrant une perte nette de 15,1 millions d'euros. Les activités sont estimées financées jusqu'au 4ème trimestre 2026

Résultats Financiers Biotechnologie Perte Nette OSE Immunotherapeutics Horizon De Trésorerie
BRIEF

published on 10/09/2025 at 16:02, 11 months 1 day ago

OSE Immunotherapeutics : Fin d'une action de concert entre actionnaires

Actionnaires Franchissement De Seuil Capital Et Droits De Vote OSE Immunotherapeutics Pacte Résilié
BRIEF

published on 10/09/2025 at 16:02, 11 months 1 day ago

OSE Immunotherapeutics: End of a concerted action between shareholders

Shareholders Threshold Crossing OSE Immunotherapeutics Capital And Voting Rights Terminated Agreement
PRESS RELEASE

published on 10/09/2025 at 15:57, 11 months 1 day ago

Franchissement de seuils
Fin de convention et action de concert chez OSE Immunotherapeutics suite à franchissement de seuils de M. Emile Loria, Mme Dominique Costantini, M. Alexis Peyroles, MS Medical Synergy SA et Aperana Consulting SARL

OSE Immunotherapeutics Franchissement Seuils Fin Convention Action Concert Emile Loria
BRIEF

published on 09/30/2025 at 19:35, 11 months 10 days ago

OSE Immunotherapeutics : Réorganisation du Conseil d'administration

Biotechnologie Conseil D'administration Immunothérapie OSE Immunotherapeutics Markus Cappel
BRIEF

published on 09/30/2025 at 19:35, 11 months 10 days ago

OSE Immunotherapeutics: Reorganization of the Board of Directors

Board Of Directors Biotechnology Immunotherapy OSE Immunotherapeutics Markus Cappel
PRESS RELEASE

published on 09/30/2025 at 19:30, 11 months 10 days ago

Renouvellement complet du Conseil d'administration Élection du Dr Markus Cappel en tant que Président du Conseil d'administration
Renouvellement complet du Conseil d'administration d'OSE Immunotherapeutics avec l'élection du Dr Markus Cappel comme Président. Assemblée Générale tenue à Paris. Nouveau Président se félicite de l'avenir prometteur de la Société

Assemblée Générale Conseil D'administration Renouvellement OSE Immunotherapeutics Dr Markus Cappel
PRESS RELEASE

published on 09/30/2025 at 19:30, 11 months 10 days ago

Full renewal of the Board of Directors Election of Dr. Markus Cappel as Chairman of the Board of Directors
OSE Immunotherapeutics renews Board of Directors and elects Dr. Markus Cappel as Chairman. Shareholders vote on key appointments

Board Of Directors Shareholders General Meeting OSE Immunotherapeutics Dr. Markus Cappel
BRIEF

published on 09/26/2025 at 07:05, 11 months 15 days ago

Partenariat stratégique pour l'innovation en immunothérapie

Partenariat Stratégique Oncologie Soutien Industriel Innovation Immunothérapie Recherche Collaborative

Accesswire

Published on 09/11/2026 at 04:00, 7 hours 44 minutes ago

Torq Announces Debt Settlement and Corporate Update
Published on 09/10/2026 at 22:25, 13 hours 19 minutes ago

Pathfinder Ventures Announces Appointment of Mickey Perret as Chief Executive Officer
Published on 09/10/2026 at 17:46, 17 hours 58 minutes ago

Groete Access Road Nears Completion
Published on 09/10/2026 at 15:20, 20 hours 24 minutes ago

MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 2026
Published on 09/10/2026 at 15:00, 20 hours 44 minutes ago

All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)

View all ACCESSWIRE

EQS Group

Published on 09/11/2026 at 11:35, 8 minutes ago

EQS-Adhoc: Correction of a release from 10/09/2026, 19:35 CET/CEST - United Internet AG: Group subsidiaries 1&1 AG and IONOS Group SE launch transformation programs
Published on 09/11/2026 at 11:30, 14 minutes ago

Galimedix Therapeutics to present functional feasibility data from Phase 2 eDREAM study in geographic atrophy at 26th EURETINA Congress
Published on 09/11/2026 at 10:15, 1 hour 29 minutes ago

TCMA Receives Two National Awards, Highlighting Thailand’s Cement Industry Progress Towards Net Zero 2050
Published on 09/11/2026 at 09:20, 2 hours 24 minutes ago

Cantourage Expands Portfolio with New Cannabis Active Ingredients for Innovative Compounded Medicines
Published on 09/11/2026 at 09:05, 2 hours 38 minutes ago

ROHM's New High Anti-surge Chip Resistors in "SDR01 Series" Achieve 0.33W Rated Power in 0402 Size

Les Echos

Published on 09/11/2026 at 07:00, 4 hours 44 minutes ago

Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 4 hours 44 minutes ago

Transparency notification by Baltisse Group
Published on 09/11/2026 at 07:00, 4 hours 44 minutes ago

BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 4 hours 44 minutes ago

BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 16 hours 14 minutes ago

Availability of the 2026 Interim Financial Report

View all LES ECHOS COMFI WIRE